Multiple sclerosis spasticity: 'State-of-the-art' questionnaire survey of specialized healthcare professionals

Expert Review of Neurotherapeutics

Volumn 13, Issue 3 SUPPL. 1, 2013, Pages 21-25

  Collongues, Nicolas ^a   Vermersch, Patrick ^b  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

epidemiology; healthcare professional; management; multiple sclerosis; questionnaire; spasticity; survey

Indexed keywords

BACLOFEN;

DISEASE SEVERITY; HEALTH CARE NEED; HEALTH CARE PERSONNEL; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE; HUMAN; INCIDENCE; MEDICAL SPECIALIST; MULTIPLE SCLEROSIS; NEUROLOGIST; PATIENT ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PHYSIOTHERAPY; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REVIEW; SPASTICITY; SYMPTOMATOLOGY;

ANTI-DYSKINESIA AGENTS; ATTITUDE OF HEALTH PERSONNEL; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; NEUROLOGY; PHYSICIANS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84873385994     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.13.10     Document Type: Review

References (14)

1. Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM 97(10), 671-676 (2004). (Pubitemid 39359325)
2. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler. 10, 589-595 (2004). (Pubitemid 39207235)
3. Oreja-Guevara C, González D, Vila C, de Sola S. Multiple sclerosis spasticity in Spain: The 6E patients' survey. Mult. Scler. 17, S80 (2011).
4. Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: The '5E' study. Expert Rev. Pharmacoecon. Outcomes Res. 11, 205-213 (2011).
5. Hass J. Pathophysiology, assessment and management of multiple sclerosis spasticity: An update. Exp. Rev. Neurother. 11(Suppl. 1), 3-8 (2011).
6. Farrar JT, Troxel A, Stott CG, Duncombe P. The validity, reliability and clinical importance of changes in spasticity severity measured on a 0-10 numerical rating scale. J. Neurol. 254(Suppl. 3), 21 (2007).
7. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: A post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin. Ther. 30(5), 974-985 (2008). (Pubitemid 351799873)
8. Arroyo R, González-Segura D, Viladrich M. Correlation between quality of life and spasticity in Spanish patients with multiple sclerosis using two different spasticity scales: The CANDLE Study. Presented at: The 28th Congress for the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10-13 October 2012.
9. Shakespeare DT, Boggild M, Young CA. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev. 4, CD001332 (2003).
10. Flachenecker P, Zettl U, Essner U, Henze T. Drug treatment of spasticity in multiple sclerosis - a cross-sectional survey in Germany. Presented at: The 28th Congress for the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 10-13 October 2012.
11. Flachenecker P, Henze T, Hengsbach M, Ehlken B, Zettl UK. Spasticity in multiple sclerosis - a cross-sectional survey in Germany. Mult. Scler. 18, S21 (2012).
12. Slof J, Gras A. Sativex® in multiple sclerosis spasticity: A cost-effectiveness model. Expert Rev. Pharmacoecon. Outcomes Res. 12(4), 525-538 (2012).
13. Delgado-Rodríguez M, Llorca J. Bias. J. Epidemiol. Commun. H. 58(8), 635-641 (2004).
14. Draugalis JR, Plaza CM. Best practices for survey research reports revisited: implications of target population, probability sampling, and response rate. Am. J. Pharm. Educ. 73(8), 142 (2009).